Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor

Characterizing the molecular immune subtype and micro-environment of lung cancer is necessary to understand immunogenic interactions between infiltrating immune and stromal cells, and how tumor cells overcome immune checkpoint blockades. This study seeks to identify computational methodologies for subtyping gene expression-based tumor-immune micro-environment interactions, which differentiate non-small cell lung cancer (NSCLC) into immune-defective and immune-competent subtypes. Here, 101 lung squamous cell carcinomas (LUSCs) and 87 lung adenocarcinomas (LUADs) tumor samples have been analyzed. Several micro-environmental factors differentially induce LUAD or LUSC immune subtypes, as well as immune checkpoint expression. In particular, tumor-associated macrophages (TAMs) are key immune cells play a vital role in inflammation and cancer micro-environments of LUSCs; whereas, regulatory B cells are immunosuppressive and tumorigenic in LUADs. Additionally, cytolytic activity upon CD8+ T cell activation is decreased by the abundance of B cells and macrophages in immune-competent subtypes. Therefore, identifying immune subtypes in lung cancer and their impact on tumor micro-environment will lead to clinical tools for assessing LUADs and LUSCs in patients, as well as maximize the efficacy of immune checkpoint inhibitors.

[1]  Andrea Bild,et al.  Alternative preprocessing of RNA-Sequencing data in The Cancer Genome Atlas leads to improved analysis results , 2015, Bioinform..

[2]  N. Rizvi,et al.  PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? , 2016, Journal of Immunotherapy for Cancer.

[3]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[4]  C. Graham,et al.  Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance , 2017, Oncotarget.

[5]  R. Rosell,et al.  Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC) , 2018, Therapeutic advances in medical oncology.

[6]  Y. Won,et al.  Lung Cancer Epidemiology in Korea , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[7]  A. Fine.  Recent trends. , 2003, Managed care quarterly.

[8]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[9]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[10]  Qi Long,et al.  Comparative transcriptomes of adenocarcinomas and squamous cell carcinomas reveal molecular similarities that span classical anatomic boundaries , 2017, PLoS genetics.

[11]  T. Chan,et al.  Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas , 2018, Journal of the National Cancer Institute.

[12]  Christodoulos Efstathiades,et al.  The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis , 2018, Front. Oncol..

[13]  D. Kranz.  Faculty Opinions recommendation of Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. , 2010 .

[14]  Peter Carmeliet,et al.  Metabolism of stromal and immune cells in health and disease , 2014, Nature.

[15]  J. Jeter,et al.  Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance , 2017, Pharmacological research.

[16]  J. Park,et al.  Epidemiology of Lung Cancer in Korea: Recent Trends , 2016, Tuberculosis and respiratory diseases.

[17]  Xiaosheng Wang,et al.  TP53 mutations, expression and interaction networks in human cancers , 2016, Oncotarget.

[18]  R. Iozzo,et al.  Tumor microenvironment: Modulation by decorin and related molecules harboring leucine‐rich tandem motifs , 2008, International journal of cancer.

[19]  Jie Du,et al.  Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers , 2016, Oncotarget.

[20]  James O. Jones,et al.  Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .

[21]  A. Ribas,et al.  SnapShot: Immune Checkpoint Inhibitors. , 2017, Cancer cell.

[22]  Chang Liu,et al.  Assessing the clinical utility of genomic expression data across human cancers , 2016, Oncotarget.

[23]  J. Welsh,et al.  Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. , 2007, Translational lung cancer research.

[24]  C. Hellweg,et al.  Intercellular Communication of Tumor Cells and Immune Cells after Exposure to Different Ionizing Radiation Qualities , 2017, Front. Immunol..

[25]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[26]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[27]  S. Turley,et al.  Immunological hallmarks of stromal cells in the tumour microenvironment , 2015, Nature Reviews Immunology.

[28]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[29]  L. Miller,et al.  Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy , 2017, Journal of Immunotherapy for Cancer.

[30]  H. Mukae,et al.  Successful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G , 2018, Thoracic cancer.

[31]  Juan Carlos Espinosa,et al.  Comprehensive Meta-Analysis , 2004 .

[32]  Yoo Jin Jung,et al.  The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.

[33]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[34]  A. Whetton,et al.  The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. , 2014, Cancer treatment reviews.

[35]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[36]  Kristina Stumpf,et al.  Tumor-associated stromal cells as key contributors to the tumor microenvironment , 2016, Breast Cancer Research.

[37]  M. Ladanyi,et al.  Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations , 2012, Clinical Cancer Research.

[38]  B. Stanger,et al.  Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer , 2016, Clinical Cancer Research.

[39]  K. Flaherty,et al.  Mechanisms of resistance to immune checkpoint inhibitors , 2018, British Journal of Cancer.

[40]  Si-Si Wang,et al.  Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer , 2018, Cellular & Molecular Immunology.

[41]  Ronald G. Crystal,et al.  Smoking-Dependent Reprogramming of Alveolar Macrophage Polarization: Implication for Pathogenesis of Chronic Obstructive Pulmonary Disease1 , 2009, The Journal of Immunology.

[42]  Jen Jen Yeh,et al.  Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma , 2015, Nature Genetics.

[43]  J. Madrigal,et al.  B cell regulation in cancer and anti-tumor immunity , 2017, Cellular &Molecular Immunology.

[44]  M. Ringnér,et al.  Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma , 2017, Nature Communications.

[45]  Atul J Butte,et al.  Comprehensive analysis of normal adjacent to tumor transcriptomes , 2017, Nature Communications.

[46]  M. Santarpia,et al.  Tumor immune microenvironment characterization and response to anti-PD-1 therapy , 2015, Cancer biology & medicine.

[47]  J. Samet,et al.  Hazard Ratio of Smoking on Lung Cancer in Korea According to Histological Type and Gender , 2016, Lung.

[48]  M. Markatou,et al.  Evaluation of Methods in Removing Batch Effects on RNA-seq Data , 2016 .

[49]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[50]  Qifeng Wang,et al.  Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma , 2018, Oncoimmunology.

[51]  J. Rosenblatt,et al.  B cell regulation of the anti-tumor response and role in carcinogenesis , 2016, Journal of Immunotherapy for Cancer.

[52]  Carl Virtanen,et al.  Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization , 2005, Oncogene.

[53]  C. Kang,et al.  Whole Exome and Transcriptome Analyses Integrated with Microenvironmental Immune Signatures of Lung Squamous Cell Carcinoma , 2018, Cancer Immunology Research.

[54]  Y. Asmann,et al.  High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma , 2017, Blood Cancer Journal.

[55]  E. Graves,et al.  The tumor microenvironment in non-small-cell lung cancer. , 2010, Seminars in radiation oncology.

[56]  R. Lockey,et al.  Detection of canonical A-to-G editing events at 3′ UTRs and microRNA target sites in human lungs using next-generation sequencing , 2015, Oncotarget.

[57]  P. Peddi,et al.  Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment , 2016, OncoTargets and therapy.